Physician

Fatima Fayyaz, MD

According to 2025 Medicare claims, Fatima Fayyaz, MD (NPI: 1962922658) practices internal medicine in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Cape May, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08210-2122.

Fayyaz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 173 traditional Medicare patients, billed 11,300 HCPCS/CPT codes, and received $87,275 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 31 prescription claims across 17 beneficiaries totaling $16,751 in drug costs. Open Payments data shows 18 records totaling $444. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,797 to $16,751. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$44K$87K2024 Medicare payment: $87,275 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
2023N/RN/RN/R
202417311,300$87,275

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$40K$79K2017 Drug cost: $1,797 (USD; Tot_Drug_Cst)2018 Drug cost: $11,761 (USD; Tot_Drug_Cst)2019 Drug cost: $6,186 (USD; Tot_Drug_Cst)2020 Drug cost: $7,091 (USD; Tot_Drug_Cst)2021 Drug cost: $7,086 (USD; Tot_Drug_Cst)2022 Drug cost: $79,495 (USD; Tot_Drug_Cst)2024 Drug cost: $16,751 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
20171651$1,797
201859191$11,761
201942138$6,186
202051184$7,091
20211417$7,086
2022N/R14$79,495
2023N/RN/RN/R
20241731$16,751

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99223Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes7377$142
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more3856$108
99232Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes3948$65
36415Insertion of needle into vein for collection of blood sample59128$9
85025Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count61126$8

Top 5 Part D drugs in 2024

By total drug costs.

Part D summary data is connected for 2024, but public drug-level costs are not available, so a Top 5 by total drug costs cannot be shown.

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.18$444Boston Scientific Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Fatima Fayyaz, MD?

Tedicare shows public-source Medicare data for Fatima Fayyaz, MD (NPI 1962922658), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Fatima Fayyaz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Fatima Fayyaz, MD?

Fatima Fayyaz, MD is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Fatima Fayyaz, MD have Open Payments data?

Fatima Fayyaz, MD has 18 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.